Bcl-2 family proteins

Bcl-2 family proteins serve as critical regulators of pathways involved in apoptosis, acting to either inhibit or promote cell death. Altered expression of these proteins occurs commonly in human cancers, contributing to neoplastic cell expansion by suppressing programmed cell death and extending tumor cell life span. Moreover, because chemotherapeutic drugs typically exert their cytotoxic actions by inducing apoptosis, the ultimate efficacy of most anticancer drugs can be heavily influenced by the relative levels and state of activation of members of the Bcl-2 family. The question of how Bcl-2 family proteins function remains debatable, but new findings are shaping our impressions of these multi-functional proteins and revealing the details of how these proteins participate in the regulation of cell life and death.

[1]  R. Schimke,et al.  BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. , 1995, Cancer research.

[2]  A. Eastman.  Apoptosis: a product of programmed and unprogrammed cell death. , 1993, Toxicology and applied pharmacology.

[3]  J. Yuan,et al.  Transducing signals of life and death. , 1997, Current opinion in cell biology.

[4]  A. Strasser,et al.  The anti‐apoptosis function of Bcl‐2 can be genetically separated from its inhibitory effect on cell cycle entry , 1997, The EMBO journal.

[5]  W. May,et al.  Bcl-2 Phosphorylation Required for Anti-apoptosis Function* , 1997, The Journal of Biological Chemistry.

[6]  J Diebold,et al.  Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). , 1996, Blood.

[7]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[8]  M. Kastan.  On the TRAIL from p53 to apoptosis? , 1997, Nature Genetics.

[9]  Yi-Te Hsu,et al.  Movement of Bax from the Cytosol to Mitochondria during Apoptosis , 1997, The Journal of cell biology.

[10]  John Calvin Reed.  Double identity for proteins of the Bcl-2 family , 1997, Nature.

[11]  John Calvin Reed.  Bcl-2: prevention of apoptosis as a mechanism of drug resistance. , 1995, Hematology/oncology clinics of North America.

[12]  H. Horvitz,et al.  C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2 , 1994, Cell.

[13]  B. Dörken,et al.  Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. , 1996, The Journal of clinical investigation.

[14]  E. Cheng,et al.  Conversion of Bcl-2 to a Bax-like death effector by caspases. , 1997, Science.

[15]  T. Tsuruo,et al.  Requirement of the Caspase-3/CPP32 Protease Cascade for Apoptotic Death following Cytokine Deprivation in Hematopoietic Cells* , 1997, The Journal of Biological Chemistry.

[16]  D. Vaux,et al.  The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. , 1997, Biochimica et biophysica acta.

[17]  G. Kroemer,et al.  Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins , 1998, Oncogene.

[18]  J. Hickman,et al.  Germinal center-derived signals act with Bcl-2 to decrease apoptosis and increase clonogenicity of drug-treated human B lymphoma cells. , 1997, Cancer research.

[19]  John Calvin Reed,et al.  Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. , 1994, Antisense research and development.

[20]  C. Thompson,et al.  Apoptosis Meets Signal Transduction: Elimination of a BAD Influence , 1996, Cell.

[21]  P. Vandenabeele,et al.  Cell death induction by receptors of the TNF family: towards a molecular understanding , 1997, FEBS letters.

[22]  John Calvin Reed.  Chronic lymphocytic leukemia: A disease of dysregulated programmed cell death* , 1997 .

[23]  I. Herr,et al.  Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells , 1996, Nature Medicine.

[24]  T. Kuwana,et al.  Apoptosis Induction by Caspase-8 Is Amplified through the Mitochondrial Release of Cytochrome c * , 1998, The Journal of Biological Chemistry.

[25]  M. Peter,et al.  Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.

[26]  D. Vaux,et al.  The molecular biology of apoptosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  C. Borner.  Diminished Cell Proliferation Associated with the Death-protective Activity of Bcl-2* , 1996, The Journal of Biological Chemistry.

[28]  U. Veronesi,et al.  The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. , 1994, Journal of the National Cancer Institute.

[29]  John Calvin Reed.  Bcl-2 and the regulation of programmed cell death , 1994, The Journal of cell biology.

[30]  J. Rouault,et al.  Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells , 1994 .

[31]  R. Poczatek,et al.  Prognostic significance of Bcl‐2 expression and p53 nuclear accumulation in colorectal adenocarcinoma , 1997, International journal of cancer.

[32]  S. Srinivasula,et al.  Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.

[33]  G. Evan,et al.  Inhibition of Ced-3/ICE-related Proteases Does Not Prevent Cell Death Induced by Oncogenes, DNA Damage, or the Bcl-2 Homologue Bak , 1997, The Journal of cell biology.

[34]  J. Houghton,et al.  Thymineless death in colon carcinoma cells is mediated via fas signaling. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  John Calvin Reed,et al.  bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. , 1992, Cancer research.

[36]  I. Weissman,et al.  Prevention of programmed cell death in Caenorhabditis elegans by human bcl-2. , 1992, Science.

[37]  A. Watson,et al.  Commitment to cell death measured by loss of clonogenicity is separable from the appearance of apoptotic markers , 1998, Cell Death and Differentiation.

[38]  A. Harris,et al.  bcl-2 protein in non-small-cell lung carcinoma. , 1993, The New England journal of medicine.

[39]  C. Thompson,et al.  Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. , 1996, Genes & development.

[40]  John Calvin Reed,et al.  Bcl-2 family proteins as ion-channels , 1998, Cell Death and Differentiation.

[41]  D C Linch,et al.  Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. , 1996, Blood.

[42]  J C Reed,et al.  Bax directly induces release of cytochrome c from isolated mitochondria. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Reed,et al.  Intracellular metabolism of Ara-C and resulting DNA fragmentation and apoptosis of human AML HL-60 cells possessing disparate levels of Bcl-2 protein. , 1996, Leukemia.

[44]  John Calvin Reed.  Balancing cell life and death: bax, apoptosis, and breast cancer. , 1996, The Journal of clinical investigation.

[45]  G. Kroemer,et al.  The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death , 1997, Oncogene.

[46]  John Calvin Reed,et al.  Somatic point mutations in the translocated bcl-2 genes of non-Hodgkin's lymphomas and lymphocytic leukemias: implications for mechanisms of tumor progression. , 1993, Leukemia & lymphoma.

[47]  J C Reed,et al.  Mitochondria and apoptosis. , 1998, Science.

[48]  John Calvin Reed,et al.  A cis-acting element in the BCL-2 gene controls expression through translational mechanisms. , 1996, Oncogene.

[49]  J C Reed,et al.  Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. , 1997, Blood.

[50]  John Calvin Reed,et al.  Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. , 1993, Blood.

[51]  J. Xiang,et al.  BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Z. Oltvai,et al.  Checkpoints of dueling dimers foil death wishes , 1994, Cell.

[53]  John Calvin Reed,et al.  Cytochrome c: Can't Live with It—Can't Live without It , 1997, Cell.

[54]  P. Galle,et al.  Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. , 1997, The Journal of clinical investigation.

[55]  John Calvin Reed.  Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. , 1995, Current opinion in oncology.

[56]  J. Hickman,et al.  bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. , 1993, Cancer research.

[57]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[58]  D. Thorley-Lawson,et al.  A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.

[59]  E. Cheng,et al.  Bax-independent inhibition of apoptosis by Bcl-XL , 1996, Nature.

[60]  C. Croce,et al.  Inactivation of Bcl-2 by phosphorylation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[61]  S. Kaufmann.  Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. , 1989, Cancer research.

[62]  Seamus J. Martin,et al.  Anti-apoptotic oncogenes prevent caspase-dependent and independent commitment for cell death , 1998, Cell Death and Differentiation.

[63]  S. Korsmeyer,et al.  Apoptosis-associated signaling pathways are required for chemotherapy-mediated female germ cell destruction , 1997, Nature Medicine.